A Phase 3 interventional study of Aliskiren and Amlodipine in Cardiovascular Events, sponsored by Novartis Pharmaceuticals. Terminated at 185 sites in 18 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2014-04-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood pressure (SBP) 130 to 159 mmHg, in preventing major cardiovascular (CV) events and on global measures of physical, executive and cognitive function.
This was 2x2 factorial design study with 2 strata. As per protocol, the first co- Primary analysis as well as secondary analysis were aliskiren based regimen vs non-aliskiren based regimen. All aliskiren based arm were combined into the aliskiren based regimen and all non-aliskiren based arms were combined into non-aliskiren based regimen.
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Systolic blood pressure 130 - 159 mmHg with any one of the following (1, 2 or 3):
Men and women aged ≥ 65 years if they have at least one of the following: (secondary prevention) Coronary heart disease
Men and women aged ≥ 65 years with no history of CVD, and with at least 1 CV risk factor (primary prevention):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol. In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum. Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period.
Drug: Aliskiren · Drug: Amlodipine
In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol. In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum. Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily.
Drug: Aliskiren · Drug: Hydrochlorothiazide (HCTZ)
In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum. In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg
Drug: Aliskiren · Drug: Placebo for Amlodipine
In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum. In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily
Drug: Aliskiren · Drug: Placebo for Hydrochlorothiazide (HCTZ)
In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum. In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily
Drug: Amlodipine · Drug: Placebo for Aliskiren
In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum. In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily
Drug: Hydrochlorothiazide (HCTZ) · Drug: Placebo for Aliskiren
In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum. In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily
Drug: Placebo for Aliskiren · Drug: Placebo for Amlodipine
In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum. In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily
Drug: Placebo for Aliskiren · Drug: Placebo for Hydrochlorothiazide (HCTZ)
Aliskiren 150/300 mg once daily
Amlodipine 5 mg
HCTZ 12.5/25 mg
Placebo for Aliskiren 300 mg
Placebo for Amlodipine
Placebo for HCTZ 12.5/25 mg
Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen
The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure
Time frame: End of study (209 days (median))
Number of Participants With Composite Cardiovascular Endpoints in Aliskiren+Amlodipine/HCTZ Group Versus All Placebo Group
The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure
Time frame: End of study (209 days (median))
Change From Baseline to End of Study in Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part I)
Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part I of SAGE included 4 dimensions: * Community Cognition (maximum of scores of questions 1 to 6); * Instrumental Activities of daily Living (IADL) (maximum of scores of questions 7 to 10); * Mobility (maximum of scores of questions 11 and 12);. * Basic Activities of daily Living (ADL) (maximum of scores of questions 13 to 15) Each dimension's total score ranged from 0 to 3. 0=best, 3=worst A negative change in value from baseline means improvement in the ability to perform everyday activities.
Time frame: Baseline, End of study (209 days [median])
Percentage of Participants With Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part II)
Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE was comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in the last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part II of SAGE included 2 dimensions: * "Normal" if the scores of all SAGE questions is 0 (i.e., No difficulty) * "Mobility Only" if scores of both SAGE questions 11 and 12 are 0
Time frame: End of study (209 days [median])
Number of Participants With Renal Dysfunction in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen
The renal dysfunction (composite endpoint) was defined as the first occurrence of either of the following: * End-stage renal disease \[ESRD\] requiring dialysis or transplantation * Doubling of serum creatinine and reaching an eGFR \< 45 ml/min/1.73 m\^2.
Time frame: End of study (209 days (median))
Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen
The total mortality endpoint was defined as time to death from any cause. Total mortality analysis used the date of last follow-up including the washout period as the censoring date.
Time frame: End of study (209 days (median))
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
Mean sitting systolic blood pressure (msSBP) is the average of 2 sitting SBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.
Time frame: Baseline (BL), 6 week, 6 month and 12 month
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
Mean sitting diastolic blood pressure (msDBP) is the average of 2 sitting DBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.
Time frame: Baseline (BL), 6 week, 6 month and 12 month
| Milestone | Aliskiren + Hydrochlorothiazide (HCTZ) | Aliskiren + Placebo for HCTZ | Aliskiren + Amlodipine | Aliskiren + Placebo for Amlodipine | HCTZ + Placebo for Aliskiren | Placebo for Aliskiren + Placebo for HCTZ | Amlodipine + Placebo for Aliskiren | Placebo for Aliskiren + Placebo for Amlodipine |
|---|---|---|---|---|---|---|---|---|
| Started | 1335 | 0 | 1001 | 0 | 0 | 0 | 0 | 0 |
| Completed | 980 | 0 | 779 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 355 | 0 | 222 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Aliskiren + Hydrochlorothiazide (HCTZ) | Aliskiren + Placebo for HCTZ | Aliskiren + Amlodipine | Aliskiren + Placebo for Amlodipine | HCTZ + Placebo for Aliskiren | Placebo for Aliskiren + Placebo for HCTZ | Amlodipine + Placebo for Aliskiren | Placebo for Aliskiren + Placebo for Amlodipine |
|---|---|---|---|---|---|---|---|---|
| Started | 244 | 232 | 189 | 195 | 251 | 253 | 196 | 199 |
| Completed | 242 | 229 | 188 | 191 | 247 | 245 | 190 | 196 |
| Not completed | 2 | 3 | 1 | 4 | 4 | 8 | 6 | 3 |
| Withdrew: Death | 1 | 1 | 1 | 2 | 1 | 5 | 2 | 1 |
| Withdrew: Withdrew informed consent/ refused visit | 1 | 1 | 0 | 2 | 2 | 1 | 1 | 1 |
| Withdrew: Other reasons | 0 | 1 | 0 | 0 | 1 | 2 | 3 | 1 |
The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure
| participants | Aliskiren Based Regimen | Non-Aliskiren Based Regimen |
|---|---|---|
| Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen | 11 | 14 |
Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part I of SAGE included 4 dimensions: * Community Cognition (maximum of scores of questions 1 to 6); * Instrumental Activities of daily Living (IADL) (maximum of scores of questions 7 to 10); * Mobility (maximum of scores of questions 11 and 12);. * Basic Activities of daily Living (ADL) (maximum of scores of questions 13 to 15) Each dimension's total score ranged from 0 to 3. 0=best, 3=worst A negative change in value from baseline means improvement in the ability to perform everyday activities.
| units on a scale | Aliskiren Based Regimen | Non-Aliskiren Based Regimen |
|---|---|---|
| Community Cognition | -0.04 ± 0.768 | -0.05 ± 0.741 |
| Instrumental Activities of daily Living (IADL) | -0.06 ± 0.562 | -0.04 ± 0.505 |
| Mobility | 0.01 ± 0.791 | 0.00 ± 0.779 |
| ADL | -0.09 ± 0.525 | -0.08 ± 0.520 |
Mean sitting systolic blood pressure (msSBP) is the average of 2 sitting SBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.
| mmHg | Aliskiren Based Regimen | Non-Aliskiren Based Regimen |
|---|---|---|
| change from Baseline to 6 week (n=821,867) | -11.9 ± 0.50 | -8.02 ± 0.48 |
| change from baseline to 6 month (n=730,775) | -10.1 ± 0.52 | -6.8 ± 0.50 |
| change from baseline to 12 month (n=397,399) | -7.7 ± 0.68 | -5.8 ± 0.68 |
The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure
| participants | Aliskiren+Amlodipine/HCTZ Group | Placebo |
|---|---|---|
| Number of Participants With Composite Cardiovascular Endpoints in Aliskiren+Amlodipine/HCTZ Group Versus All Placebo Group | 2 | 8 |
Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE was comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in the last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part II of SAGE included 2 dimensions: * "Normal" if the scores of all SAGE questions is 0 (i.e., No difficulty) * "Mobility Only" if scores of both SAGE questions 11 and 12 are 0
| percentage of participants | Aliskiren Based Regimen | Non-Aliskiren Based Regimen |
|---|---|---|
| Normal | 44.2 | 46.5 |
| Mobility Only | 66.8 | 68.6 |
The renal dysfunction (composite endpoint) was defined as the first occurrence of either of the following: * End-stage renal disease \[ESRD\] requiring dialysis or transplantation * Doubling of serum creatinine and reaching an eGFR \< 45 ml/min/1.73 m\^2.
| participants | Aliskiren Based Regimen | Non-Aliskiren Based Regimen |
|---|---|---|
| ESRD requiring dialysis or transplantation | 0 | 0 |
| Doubling of creatinine & eGFR<45 ml/min/1.73 m^2 | 7 | 1 |
Mean sitting diastolic blood pressure (msDBP) is the average of 2 sitting DBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.
| mmHg | Aliskiren Based Regimen | Non-Aliskiren Based Regimen |
|---|---|---|
| change from Baseline to 6 week (n=821,867) | -5.6 ± 0.31 | -3.6 ± 0.30 |
| change from baseline to 6 month (n=730,775) | -4.9 ± 0.33 | -3.5 ± 0.32 |
| change from baseline to 12 month (n=397,399) | -4.3 ± 0.43 | -3.9 ± 0.43 |
The total mortality endpoint was defined as time to death from any cause. Total mortality analysis used the date of last follow-up including the washout period as the censoring date.
| Participants | Aliskiren Based Regimen | Non-Aliskiren Based Regimen |
|---|---|---|
| Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen | 5 | 9 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Period: Aliskiren + Hydrochlorothiazide (HCTZ) | — | 10/1,335 (0.7%) | 7/1,335 (0.5%) |
| Run-in Period: Aliskiren + Amlodipine | — | 10/1,001 (1%) | 19/1,001 (1.9%) |
| Double Blind Period: Aliskiren + Hydrochlorothiazide (HCTZ) | — | 8/244 (3.3%) | 6/244 (2.5%) |
| Double Blind Period: Aliskiren + Placebo for HCTZ | — | 5/232 (2.2%) | 5/232 (2.2%) |
| Double Blind Period: Aliskiren + Amlodipine | — | 7/189 (3.7%) | 9/189 (4.8%) |
| Double Blind Period: Aliskiren + Placebo for Amlodipine | — | 8/195 (4.1%) | 8/195 (4.1%) |
| Double Blind Period: HCTZ + Placebo for Aliskiren | — | 4/251 (1.6%) | 6/251 (2.4%) |
| Double Blind Period: Placebo for Aliskiren + Placebo for HCTZ | — | 6/253 (2.4%) | 5/253 (2%) |
| Double Blind Period: Amlodipine + Placebo for Aliskiren | — | 3/196 (1.5%) | 14/196 (7.1%) |
| Double Blind Period: Placebo for Aliskiren + Placebo for Amlod | — | 7/199 (3.5%) | 3/199 (1.5%) |
| Event | Run-in Period: Aliskiren + Hydrochlorothiazide (HCTZ) | Run-in Period: Aliskiren + Amlodipine | Double Blind Period: Aliskiren + Hydrochlorothiazide (HCTZ) | Double Blind Period: Aliskiren + Placebo for HCTZ | Double Blind Period: Aliskiren + Amlodipine | Double Blind Period: Aliskiren + Placebo for Amlodipine | Double Blind Period: HCTZ + Placebo for Aliskiren | Double Blind Period: Placebo for Aliskiren + Placebo for HCTZ | Double Blind Period: Amlodipine + Placebo for Aliskiren | Double Blind Period: Placebo for Aliskiren + Placebo for Amlod |
|---|---|---|---|---|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 2/1335 | 1/1001 | 1/244 | 0/232 | 3/189 | 1/195 | 0/251 | 0/253 | 1/196 | 0/199 |
| SyncopeNervous system disorders | 0/1335 | 1/1001 | 3/244 | 0/232 | 1/189 | 0/195 | 0/251 | 0/253 | 0/196 | 0/199 |
| Renal failureRenal and urinary disorders | 0/1335 | 0/1001 | 2/244 | 1/232 | 0/189 | 0/195 | 0/251 | 0/253 | 0/196 | 0/199 |
| Electrolyte imbalanceMetabolism and nutrition disorders | 0/1335 | 0/1001 | 0/244 | 0/232 | 1/189 | 0/195 | 0/251 | 0/253 | 0/196 | 0/199 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1335 | 1/1001 | 0/244 | 0/232 | 1/189 | 0/195 | 0/251 | 0/253 | 0/196 | 1/199 |
| HemiparesisNervous system disorders | 0/1335 | 0/1001 | 0/244 | 0/232 | 1/189 | 0/195 | 0/251 | 0/253 | 0/196 | 0/199 |
| ParaesthesiaNervous system disorders | 0/1335 | 0/1001 | 0/244 | 0/232 | 1/189 | 0/195 | 0/251 | 0/253 | 0/196 | 0/199 |
| Psychotic disorderPsychiatric disorders | 0/1335 | 0/1001 | 0/244 | 0/232 | 1/189 | 0/195 | 0/251 | 0/253 | 0/196 | 0/199 |
| CholecystitisHepatobiliary disorders | 0/1335 | 0/1001 | 0/244 | 0/232 | 0/189 | 1/195 | 0/251 | 0/253 | 0/196 | 0/199 |
| CellulitisInfections and infestations | 0/1335 | 0/1001 | 0/244 | 0/232 | 0/189 | 1/195 | 1/251 | 0/253 | 0/196 | 0/199 |
| Event | Run-in Period: Aliskiren + Hydrochlorothiazide (HCTZ) | Run-in Period: Aliskiren + Amlodipine | Double Blind Period: Aliskiren + Hydrochlorothiazide (HCTZ) | Double Blind Period: Aliskiren + Placebo for HCTZ | Double Blind Period: Aliskiren + Amlodipine | Double Blind Period: Aliskiren + Placebo for Amlodipine | Double Blind Period: HCTZ + Placebo for Aliskiren | Double Blind Period: Placebo for Aliskiren + Placebo for HCTZ | Double Blind Period: Amlodipine + Placebo for Aliskiren | Double Blind Period: Placebo for Aliskiren + Placebo for Amlod |
|---|---|---|---|---|---|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 0/1335 | 7/1001 | 0/244 | 1/232 | 4/189 | 0/195 | 0/251 | 2/253 | 7/196 | 1/199 |
| HypotensionVascular disorders | 3/1335 | 5/1001 | 4/244 | 3/232 | 6/189 | 2/195 | 4/251 | 1/253 | 5/196 | 1/199 |
| GastritisGastrointestinal disorders | 0/1335 | 0/1001 | 0/244 | 0/232 | 0/189 | 2/195 | 0/251 | 0/253 | 1/196 | 1/199 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/1335 | 0/1001 | 1/244 | 1/232 | 0/189 | 2/195 | 1/251 | 1/253 | 1/196 | 0/199 |
| DizzinessNervous system disorders | 3/1335 | 7/1001 | 1/244 | 0/232 | 0/189 | 2/195 | 1/251 | 1/253 | 0/196 | 0/199 |
Full analysis Set (FAS): All randomized patients, regardless of receiving study medication.
| Age, Customized(participants) | Aliskiren + Hydrochlorothiazide (HCTZ) | Aliskiren + Placebo for HCTZ | Aliskiren + Amlodipine | Aliskiren + Placebo for Amlodipine | HCTZ + Placebo for Aliskiren | Placebo for Aliskiren + Placebo for HCTZ | Amlodipine + Placebo for Aliskiren | Placebo for Aliskiren + Placebo for Amlodipine | Total |
|---|---|---|---|---|---|---|---|---|---|
| >=65 to <75 years | 165 | 174 | 127 | 125 | 180 | 189 | 135 | 134 | 1229 |
| >=75 years | 79 | 58 | 62 | 70 | 71 | 64 | 61 | 65 | 530 |
| Sex: Female, Male(Participants) | Aliskiren + Hydrochlorothiazide (HCTZ) | Aliskiren + Placebo for HCTZ | Aliskiren + Amlodipine | Aliskiren + Placebo for Amlodipine | HCTZ + Placebo for Aliskiren | Placebo for Aliskiren + Placebo for HCTZ | Amlodipine + Placebo for Aliskiren | Placebo for Aliskiren + Placebo for Amlodipine | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 119 | 109 | 91 | 89 | 122 | 108 | 87 | 88 | 813 |
| Male | 125 | 123 | 98 | 106 | 129 | 145 | 109 | 111 | 946 |
Showing the first 100 of 185 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aliskiren · Amlodipine · Hydrochlorothiazide